Sequencing first-line CDK4/6 inhibitors in metastatic breast cancer [Video]

Stephanie Graff, MD, FACP, FASCO, Brown University, Providence, RI, comments on the role of CDK4/6 inhibitors such as palbociclib, ribociclib, and abemaciclib for patients with metastatic breast cancer. Whilst ribociclib has been proven to have a statistically significant overall survival advantage, abemaciclib does not in the MONARCH 3 (NCT02246621) when combined with aromatase inhibitors. CDK4/6 inhibitors in general are typically used in the first-line setting based on tolerability and comorbidities and ribociclib is often the inhibitor of choice. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.